Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus ClopidogrelJacob A. Doll, Keith A.A. Fox, E. Magnus Ohman et al.|Journal of the American College of Cardiology|2016Cited by 39
The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery diseaseThomas O. Bergmeijer, Paul A. Gurbel, Udaya S. Tantry et al.|Thrombosis and Haemostasis|2014Cited by 32
Clopidogrel metaboliser status based on point-of-care CYP2C19 genetic testing in patients with coronary artery diseaseStefan James, David Erlinge, Suman Duvvuru et al.|Thrombosis and Haemostasis|2014Cited by 21
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysDominick J Angiolillo, Oscar Ö. Braun, José Luis Ferreiro et al.|Thrombosis and Haemostasis|2013Cited by 18
TCT-725 Point-of-Care Genetic Testing of Eleven CYP2C19 Single Nucleotide Polymorphisms Identifies Extensive and Reduced Metabolizers of Clopidogrel With High Accuracy in Patients With Coronary Artery DiseaseDavid Erlinge, Paul A. Gurbel, Stefan James et al.|Journal of the American College of Cardiology|2012Cited by 1